ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer

Gastroenterology

Volumn 151, Issue 4, 2016, Pages 637-650.e10

  Chan, Tim Hon Man ^a   Qamra, Aditi ^b,c   Tan, Kar Tong ^a   Guo, Jing ^a   Yang, Henry ^a   Qi, Lihua ^a   Lin, Jaymie Siqi ^a   Ng, Vanessa Hui En ^a   Song, Yangyang ^a   Hong, Huiqi ^a   Tay, Su Ting ^d   Liu, Yujing ^d,e   Lee, Jeeyun ^f   Rha, Sun Yong ^g   Zhu, Feng ^c   So, Jimmy Bok Yan ^c   Teh, Bin Tean ^a,d,h   Yeoh, Khay Guan ^i,j   Rozen, Steve ^d   Tenen, Daniel G ^a,k   Tan, Patrick ^a,b,d,h   Chen, Leilei ^a,c   more..

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

ⁱ Dept Medicine Endocrinol Diabet   (Singapore)

^j NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^k HARVARD STEM CELL INSTITUTE   (United States)

more..

Author keywords

ADARs; Editome; RNA Editing; Transcriptome

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE THAT ACT ON RNA; ARGININE; HISTIDINE; PODOCALYXIN LIKE; RNA; UNCLASSIFIED DRUG; ADAR1 PROTEIN, HUMAN; ADARB1 PROTEIN, HUMAN; CODON; PODOCALYXIN; RNA BINDING PROTEIN; SIALOGLYCOPROTEIN; TRANSCRIPTOME;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CODON; CONTROLLED STUDY; ENZYME ACTIVE SITE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NEXT GENERATION SEQUENCING; PHENOTYPE; PRIORITY JOURNAL; RNA EDITING; STOMACH CANCER; STOMACH CARCINOGENESIS; SURVIVAL PREDICTION; TRANSCRIPTOMICS; DISEASE COURSE; FEMALE; GENETIC EPIGENESIS; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEQUENCE ANALYSIS; STOMACH TUMOR;

ADENOSINE DEAMINASE; CODON; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RNA EDITING; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, RNA; SIALOGLYCOPROTEINS; STOMACH NEOPLASMS; TRANSCRIPTOME;

EID: 84989817021     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.06.043     Document Type: Article

References (61)

1. 1 Hartgrink, H.H., Jansen, E.P., van Grieken, N.C., et al. Gastric cancer. Lancet 374 (2009), 477–490.
2. 2 Parkin, D.M., Bray, F., Ferlay, J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005), 74–108.
3. 3 Tan, P., Yeoh, K.G., Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology 149 (2015), 1153–1162.e3.
4. 4 Wang, K., Yuen, S.T., Xu, J., et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46 (2014), 573–582.
5. 5 Kimura, Y., Noguchi, T., Kawahara, K., et al. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 17 (2004), 1328–1337.
6. 6 Strickler, J.G., Zheng, J., Shu, Q., et al. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 54 (1994), 4750–4755.
7. 7 McLean, M.H., El-Omar, E.M., Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 11 (2014), 664–674.
8. 8 Lee, J., Lee, S.E., Kang, S.Y., et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119 (2013), 1627–1635.
9. 9 Tao, J., Deng, N.T., Ramnarayanan, K., et al. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med, 3, 2011, 77ra30.
10. 10 Yao, F., Kausalya, J.P., Sia, Y.Y., et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep 12 (2015), 272–285.
11. 11 Boku, N., HER2-positive gastric cancer. Gastric Cancer 17 (2014), 1–12.
12. 12 Fuchs, C.S., Tomasek, J., Yong, C.J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
13. 13 Zouridis, H., Deng, N., Ivanova, T., et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med, 4, 2012, 156ra140.
14. 14 Figueroa, M.E., Lugthart, S., Li, Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17 (2010), 13–27.
15. 15 Park, S.Y., Kook, M.C., Kim, Y.W., et al. CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch 457 (2010), 415–422.
16. 16 Farajollahi, S., Maas, S., Molecular diversity through RNA editing: a balancing act. Trends Genet 26 (2010), 221–230.
17. 17 Qi, L., Chan, T.H., Tenen, D.G., et al. RNA editome imbalance in hepatocellular carcinoma. Cancer Res 74 (2014), 1301–1306.
18. 18 Athanasiadis, A., Rich, A., Maas, S., Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol, 2, 2004, e391.
19. 19 Nishikura, K., Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol 7 (2006), 919–931.
20. 20 Chan, T.H., Lin, C.H., Qi, L., et al. A disrupted RNA editing balance mediated by ADARs (adenosine deaminases that act on RNA) in human hepatocellular carcinoma. Gut 63 (2014), 832–843.
21. 21 Qin, Y.R., Qiao, J.J., Chan, T.H., et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res 74 (2014), 840–851.
22. 22 Chen, L., Li, Y., Lin, C.H., et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 19 (2013), 209–216.
23. 23 Ramaswami, G., Li, J.B., RADAR: a rigorously annotated database of A-to-I RNA editing. Nucleic Acids Res 42 (2014), D109–D113.
24. 24 Li, J.B., Levanon, E.Y., Yoon, J.K., et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 324 (2009), 1210–1213.
25. 25 Bass, B.L., RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 71 (2002), 817–846.
26. 26 Peng, Z., Cheng, Y., Tan, B.C., et al. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nat Biotechnol 30 (2012), 253–260.
27. 27 Paz, N., Levanon, E.Y., Amariglio, N., et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 17 (2007), 1586–1595.
28. 28 Ramaswami, G., Lin, W., Piskol, R., et al. Accurate identification of human Alu and non-Alu RNA editing sites. Nat Methods 9 (2012), 579–581.
29. 29 Picardi, E., Manzari, C., Mastropasqua, F., et al. Profiling RNA editing in human tissues: towards the inosinome Atlas. Sci Rep, 5, 2015, 14941.
30. 30 Cenci, C., Barzotti, R., Galeano, F., et al. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem 283 (2008), 7251–7260.
31. 31 Maas, S., Patt, S., Schrey, M., et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A 98 (2001), 14687–14692.
32. 32 Samuel, C.E., Antiviral actions of interferons. Clin Microbiol Rev 14 (2001), 778–809 table of contents.
33. 33 Sato, S., Wong, S.K., Lazinski, D.W., Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2. J Virol 75 (2001), 8547–8555.
34. 34 Wong, S.K., Lazinski, D.W., Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1. Proc Natl Acad Sci U S A 99 (2002), 15118–15123.
35. 35 Wu, Y., Grabsch, H., Ivanova, T., et al. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut 62 (2013), 1100–1111.
36. 36 Lee, J., Sohn, I., Do, I.G., et al. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One, 9, 2014, e90133.
37. 37 Lai, F., Drakas, R., Nishikura, K., Mutagenic analysis of double-stranded RNA adenosine deaminase, a candidate enzyme for RNA editing of glutamate-gated ion channel transcripts. J Biol Chem 270 (1995), 17098–17105.
38. 38 Ota, H., Sakurai, M., Gupta, R., et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153 (2013), 575–589.
39. 39 Jiang, Q., Crews, L.A., Barrett, C.L., et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A 110 (2013), 1041–1046.
40. 40 Choudhury, Y., Tay, F.C., Lam, D.H., et al. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest 122 (2012), 4059–4076.
41. 41 Nemlich, Y., Greenberg, E., Ortenberg, R., et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest 123 (2013), 2703–2718.
42. 42 Shoshan, E., Mobley, A.K., Braeuer, R.R., et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol 17 (2015), 311–321.
43. 43 Han, S.W., Kim, H.P., Shin, J.Y., et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer. J Exp Med 211 (2014), 613–621.
44. 44 Han, L., Diao, L., Yu, S., et al. The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers. Cancer Cell 28 (2015), 515–528.
45. 45 Paz-Yaacov, N., Bazak, L., Buchumenski, I., et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep 13 (2015), 267–276.
46. 46 Patil, V., Pal, J., Somasundaram, K., Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget 6 (2015), 43452–43471.
47. 47 Keegan, L.P., Gallo, A., O'Connell, M.A., The many roles of an RNA editor. Nat Rev Genet 2 (2001), 869–878.
48. 48 Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45 (2013), 1113–1120.
49. 49 Fumagalli, D., Gacquer, D., Rothe, F., et al. Principles governing A-to-I RNA editing in the breast cancer transcriptome. Cell Rep 13 (2015), 277–289.
50. 50 Carroll, D., A CRISPR approach to gene targeting. Mol Ther 20 (2012), 1658–1660.
51. 51 Schirle, N.T., Goodman, R.A., Krishnamurthy, M., et al. Selective inhibition of ADAR2-catalyzed editing of the serotonin 2c receptor pre-mRNA by a helix-threading peptide. Org Biomol Chem 8 (2010), 4898–4904.
52. 52 Mizrahi, R.A., Schirle, N.T., Beal, P.A., Potent and selective inhibition of A-to-I RNA editing with 2'-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides. ACS Chem Biol 8 (2013), 832–839.
53. 53 Gallo, A., Keegan, L.P., Ring, G.M., et al. An ADAR that edits transcripts encoding ion channel subunits functions as a dimer. EMBO J 22 (2003), 3421–3430.
54. 54 Wohrer, S.S., Raderer, M., Hejna, M., Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15 (2004), 1585–1595.
55. 1 Ramaswami, G., Lin, W., Piskol, R., et al. Accurate identification of human Alu and non-Alu RNA editing sites. Nat Methods 9 (2012), 579–581.
56. 2 Li, H., Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
57. 3 Ramaswami, G., Zhang, R., Piskol, R., et al. Identifying RNA editing sites using RNA sequencing data alone. Nat Methods 10 (2013), 128–132.
58. 4 Ritchie, M.E., Phipson, B., Wu, D., et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43, 2015, e47.
59. 5 Mortazavi, A., Williams, B.A., McCue, K., et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5 (2008), 621–628.
60. 6 Chan, T.H., Lin, C.H., Qi, L., et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 63 (2014), 832–843.
61. 7 Chen, L., Li, Y., Lin, C.H., et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 19 (2013), 209–216.